U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07865442) titled 'First in Human, Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of ALT-01 in Healthy Participants' on Oct. 03.
Brief Summary: The primary objective of the study is to evaluate the safety and tolerability of ALT-01 in healthy participants
Study Start Date: Oct. 26
Study Type: INTERVENTIONAL
Condition:
Autoimmune Disease
Intervention:
DRUG: ALT-01
Subcutaneous injection
DRUG: Placebo
Subcutaneous injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Altis Medicines, Inc
Disclaimer: Curated by HT Syndication....